PACB Stock News 4.47 05/13/2014 08:51:34 Pacific Biosciences

Pacific Biosciences of California (PACB) 4.47 $PACB

Short Squeeze Starting on Pacific Biosciences of California (PACB)
M2 - Fri May 02, 9:21AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report on Pacific Biosciences of California (NASDAQ: PACB). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $4.79 and the projected fundamental valuation of $8.00.

Top Gainers Technical Data -- Research on Vonage Holdings, YY Inc., Pacific Biosciences of California, and RingCentral
PR Newswire - Fri May 02, 7:04AM CDT
The US markets finished on a mixed note on Thursday, May 01, 2014, with the NASDAQ Composite closing at 4,127.45, up 0.31%, the Dow Jones Industrial Average ending the session at 16,558.87, down 0.13% and the S&P 500 finishing 0.01% lower at 1,883.68. During the trading session, five out of ten sectors finished on a positive note. A number of stocks saw large movements, including Vonage Holdings Corp (NYSE: VG), YY Inc. (NASDAQ: YY), Pacific Biosciences of California Inc. (NASDAQ: PACB) and RingCentral Inc. (NYSE: RNG). Free technical research on VG, YY, PACB and RNG can be downloaded upon signing up at:

Nasdaq stocks posting largest percentage increases
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Why Merrimack Pharmaceuticals, Weight Watchers, and Pacific Biosciences of California Are Today's 3
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 4:15PM CDT
For a second consecutive day, investors were overwhelmed with economic data and earnings, causing much confusion and very little change in the broad-based S&P 500 . Weighing the index down today was the weekly release of jobless claims...

Why Pacific Biosciences of California (PACB) Stock Is Surging Today
at The Street - Thu May 01, 1:15PM CDT
Pacific Biosciences of California (PACB) surged Thursday after the company reported first-quarter earnings that beat analysts' expectations.

Why Pacific Biosciences of California Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 12:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Pacific Biosciences of California , a...

Pacific Biosciences of California Down -2.3% Since SmarTrend Downtrend Call (PACB)
Comtex SmarTrend(R) - Thu May 01, 11:16AM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQACB) on March 27th, 2014 at $5.24. In approximately 1 month, Pacific Biosciences of California has returned 2.29% as of today's recent price of $5.36.

Upgrade Alert for Pacific Biosciences of California (PACB)
Comtex SmarTrend(R) - Thu May 01, 7:01AM CDT
Pacific Biosciences of California (NASDAQACB) was upgraded from Underweight to Neutral at JP Morgan today. The stock closed yesterday at $4.42 on volume of 640,000 shares, below average daily volume of 744,000. Pacific Biosciences of California Inc. has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. The Company's system enables real-time analysis of biomolecules with single molecule resolution.

Pacific Biosciences of California, Inc. Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 30, 3:01PM CDT
Pacific Biosciences of California, Inc. (NasdaqACB) today announced financial results for its first quarter ended March 31, 2014.

HistoGenetics Selects PacBio(R) DNA Sequencing Platform to Enhance Human Leukocyte Antigen (HLA) Typing
GlobeNewswire - Tue Apr 29, 9:29AM CDT
Pacific Biosciences of California, Inc., (NasdaqACB) and HistoGenetics, a global leader in Human Leukocyte Antigen (HLA) sequence-based typing (SBT), announced today that HistoGenetics has selected the PacBio DNA Sequencing platform for its unique ability to sequence full-length HLA genes and to provide fully phased HLA alleles. HistoGenetics has purchased two PacBio RS II DNA Sequencing systems, which will be used for HLA typing and will be evaluated as potential replacements for Sanger sequencing.

Illumina Inc's Seemingly Endless Victory Lap
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
It gets harder and harder to criticize a company's valuation when that company continues to surpass expectations and build its lead on its rivals. That is the basic story for Illumina , as this company continues to distance itself from Thermo...

Pacific Biosciences Releases Software Upgrade to Support Full-Length Transcript Sequencing and HLA Haplotype Phasing
GlobeNewswire - Mon Mar 31, 6:30AM CDT
Pacific Biosciences of California, Inc., (NasdaqACB) provider of the PacBio RS II, today announced the release of a software upgrade for its Single Molecule, Real-Time (SMRT) DNA Sequencing platform. SMRT Analysis 2.2 provides enhanced functionality to support two additional applications that uniquely benefit from the company's long-read sequencing technology: Iso-Seq(TM) full-length transcript/isoform sequencing, and human leukocyte antigen (HLA) haplotype phasing.

Pacific Biosciences of California Has Returned 14.6% Since SmarTrend Recommendation (PACB)
Comtex SmarTrend(R) - Mon Mar 24, 10:00AM CDT
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQACB) on December 16th, 2013 at $5.06. In approximately 3 months, Pacific Biosciences of California has returned 14.62% as of today's recent price of $5.80.

Pacific Biosciences of California Shares Up 19.6% Since SmarTrend's Buy Recommendation (PACB)
Comtex SmarTrend(R) - Mon Mar 17, 9:19AM CDT
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQACB) on December 16th, 2013 at $5.06. In approximately 3 months, Pacific Biosciences of California has returned 19.57% as of today's recent price of $6.05.

31.8% Return Seen to Date on SmarTrend Pacific Biosciences of California Call (PACB)
Comtex SmarTrend(R) - Fri Mar 07, 4:56PM CST
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQACB) on December 16th, 2013 at $5.06. In approximately 3 months, Pacific Biosciences of California has returned 31.82% as of today's recent price of $6.67.

PacBio, the Post-Hype Sleeper of Genomics
Luke Timmerman, The Motley Fool - Motley Fool - Mon Mar 03, 1:22PM CST
Hype and biotech go hand in hand, but genomics takes exaggeration up  a few extra notches . When genomics companies fail, they tend to crash especially hard. Yet every now and then, a company that is monumentally hyped falls flat and then figures out...